|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MZB1 |
Gene summary for MZB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MZB1 | Gene ID | 51237 |
| Gene name | marginal zone B and B1 cell specific protein | |
| Gene Alias | MEDA-7 | |
| Cytomap | 5q31.2 | |
| Gene Type | protein-coding | GO ID | GO:0001775 | UniProtAcc | Q8WU39 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51237 | MZB1 | C46 | Human | Oral cavity | OSCC | 6.82e-06 | 1.12e-01 | 0.1673 |
| 51237 | MZB1 | C57 | Human | Oral cavity | OSCC | 4.09e-02 | 4.18e-01 | 0.1679 |
| 51237 | MZB1 | C07 | Human | Oral cavity | OSCC | 3.21e-02 | 2.89e-01 | 0.2491 |
| 51237 | MZB1 | C08 | Human | Oral cavity | OSCC | 8.14e-03 | 8.78e-02 | 0.1919 |
| 51237 | MZB1 | LN22 | Human | Oral cavity | OSCC | 1.23e-08 | 1.12e+00 | 0.1733 |
| 51237 | MZB1 | LN46 | Human | Oral cavity | OSCC | 5.47e-03 | 1.78e-01 | 0.1666 |
| 51237 | MZB1 | LP15 | Human | Oral cavity | LP | 2.83e-14 | 1.95e+00 | 0.2174 |
| 51237 | MZB1 | EOLP-1 | Human | Oral cavity | EOLP | 8.54e-04 | 1.87e-01 | -0.0202 |
| 51237 | MZB1 | SYSMH6 | Human | Oral cavity | OSCC | 2.52e-02 | 6.51e-01 | 0.1275 |
| 51237 | MZB1 | Dong_P1 | Human | Prostate | Tumor | 2.31e-10 | 2.63e-01 | 0.035 |
| 51237 | MZB1 | GSM5353216_PA_PB1A_Pool_1_3_S50_L002 | Human | Prostate | Tumor | 2.22e-03 | 6.34e-01 | 0.159 |
| 51237 | MZB1 | GSM5353218_PA_PB1B_Pool_1_2_S74_L003 | Human | Prostate | Tumor | 2.46e-15 | 1.49e+00 | 0.1479 |
| 51237 | MZB1 | GSM5353220_PA_PB1B_Pool_3_S51_L002 | Human | Prostate | Tumor | 6.76e-14 | 1.38e+00 | 0.1531 |
| 51237 | MZB1 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 4.53e-02 | 3.40e-01 | 0.1633 |
| 51237 | MZB1 | GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002 | Human | Prostate | Tumor | 3.27e-04 | 6.29e-01 | 0.1619 |
| 51237 | MZB1 | GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002 | Human | Prostate | Tumor | 4.40e-03 | 6.00e-01 | 0.159 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:190165316 | Oral cavity | OSCC | cellular response to peptide | 194/7305 | 359/18723 | 4.31e-09 | 9.57e-08 | 194 |
| GO:003286916 | Oral cavity | OSCC | cellular response to insulin stimulus | 114/7305 | 203/18723 | 5.07e-07 | 7.41e-06 | 114 |
| GO:007137510 | Oral cavity | OSCC | cellular response to peptide hormone stimulus | 153/7305 | 290/18723 | 1.23e-06 | 1.63e-05 | 153 |
| GO:004343419 | Oral cavity | OSCC | response to peptide hormone | 208/7305 | 414/18723 | 1.83e-06 | 2.35e-05 | 208 |
| GO:003286816 | Oral cavity | OSCC | response to insulin | 138/7305 | 264/18723 | 7.54e-06 | 8.15e-05 | 138 |
| GO:00082868 | Oral cavity | OSCC | insulin receptor signaling pathway | 67/7305 | 116/18723 | 3.23e-05 | 2.91e-04 | 67 |
| GO:00466263 | Oral cavity | OSCC | regulation of insulin receptor signaling pathway | 38/7305 | 66/18723 | 1.70e-03 | 8.07e-03 | 38 |
| GO:00706618 | Oral cavity | OSCC | leukocyte proliferation | 145/7305 | 318/18723 | 9.31e-03 | 3.33e-02 | 145 |
| GO:00027022 | Oral cavity | OSCC | positive regulation of production of molecular mediator of immune response | 58/7305 | 117/18723 | 1.28e-02 | 4.27e-02 | 58 |
| GO:00466517 | Oral cavity | OSCC | lymphocyte proliferation | 131/7305 | 288/18723 | 1.41e-02 | 4.67e-02 | 131 |
| GO:0043434110 | Oral cavity | LP | response to peptide hormone | 138/4623 | 414/18723 | 4.00e-05 | 5.87e-04 | 138 |
| GO:190165317 | Oral cavity | LP | cellular response to peptide | 122/4623 | 359/18723 | 4.22e-05 | 6.10e-04 | 122 |
| GO:003286817 | Oral cavity | LP | response to insulin | 88/4623 | 264/18723 | 9.19e-04 | 7.82e-03 | 88 |
| GO:003286917 | Oral cavity | LP | cellular response to insulin stimulus | 70/4623 | 203/18723 | 1.07e-03 | 8.96e-03 | 70 |
| GO:007137515 | Oral cavity | LP | cellular response to peptide hormone stimulus | 95/4623 | 290/18723 | 1.12e-03 | 9.19e-03 | 95 |
| GO:190165323 | Oral cavity | EOLP | cellular response to peptide | 85/2218 | 359/18723 | 2.06e-10 | 2.06e-08 | 85 |
| GO:004343424 | Oral cavity | EOLP | response to peptide hormone | 89/2218 | 414/18723 | 1.29e-08 | 6.11e-07 | 89 |
| GO:003286922 | Oral cavity | EOLP | cellular response to insulin stimulus | 53/2218 | 203/18723 | 1.65e-08 | 7.43e-07 | 53 |
| GO:007137523 | Oral cavity | EOLP | cellular response to peptide hormone stimulus | 68/2218 | 290/18723 | 1.98e-08 | 8.62e-07 | 68 |
| GO:003286823 | Oral cavity | EOLP | response to insulin | 62/2218 | 264/18723 | 7.78e-08 | 2.76e-06 | 62 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MZB1 | SNV | Missense_Mutation | c.488G>T | p.Arg163Leu | p.R163L | Q8WU39 | protein_coding | tolerated(0.23) | benign(0.111) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR | |
| MZB1 | insertion | Frame_Shift_Ins | novel | c.341_342insCTTGCTCA | p.Gly115LeufsTer17 | p.G115Lfs*17 | Q8WU39 | protein_coding | TCGA-A8-A08S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | ||
| MZB1 | SNV | Missense_Mutation | rs374843946 | c.239G>A | p.Arg80Gln | p.R80Q | Q8WU39 | protein_coding | tolerated(0.76) | benign(0.001) | TCGA-AA-A022-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MZB1 | SNV | Missense_Mutation | rs372851416 | c.488N>A | p.Arg163Gln | p.R163Q | Q8WU39 | protein_coding | tolerated(0.65) | benign(0.001) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| MZB1 | SNV | Missense_Mutation | novel | c.190C>A | p.Leu64Met | p.L64M | Q8WU39 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| MZB1 | SNV | Missense_Mutation | c.204N>T | p.Glu68Asp | p.E68D | Q8WU39 | protein_coding | deleterious(0.04) | benign(0.096) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MZB1 | SNV | Missense_Mutation | rs375343363 | c.145N>T | p.Arg49Cys | p.R49C | Q8WU39 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EO-A3AZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| MZB1 | SNV | Missense_Mutation | c.557N>C | p.Arg186Thr | p.R186T | Q8WU39 | protein_coding | deleterious_low_confidence(0) | benign(0.077) | TCGA-95-8494-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MZB1 | SNV | Missense_Mutation | novel | c.503N>T | p.Ala168Val | p.A168V | Q8WU39 | protein_coding | tolerated(0.22) | benign(0.011) | TCGA-98-A53B-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| MZB1 | SNV | Missense_Mutation | c.533N>T | p.Cys178Phe | p.C178F | Q8WU39 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |